Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOLT and CD3+/CD19+ Depleted BMT for PID
NCT03330795Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2017
- Primary completion
- Mar 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of CD3/CD19 depleted hematopoietic stem cells in primary immunodeficiency (PI), sponsored by National Institute of Allergy and Infectious Diseases. Started Dec 2017; status: completed.
02
Drugs
CD3/CD19 depleted hematopoietic stem cells
03
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT03330795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03330795.